LSR goes private in Lion Holdings takeover

- Last updated on GMT

Related tags: Stock market, Stock

US CRO Life Science Research has become a private company with the completion of its acquisition by Lion Holdings, an investment vehicle owner by CEO Andrew Baker.

The firm, which was set up to move Huntingdon Life Sciences’ financial centre to the US, delisted from the New York Stock Exchange on November 25 after shareholders approved Lion’s $8.50 per share buyout.

Like many preclinical contract research organisations (CRO), LSR has had a difficult 2009 with progressive quarterly reports dominated by falling revenues and operating income.

Related news

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars